Munir Janmohamed, MD
Advanced Heart Failure and Transplant Cardiology · Sacramento, CANPI 1194840694
Payments from drug & device makers
Across 641 payments — averaging $691.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$116K
- Abbott$100K
- Amgen$51K
- AstraZeneca$37K
- Novartis$35K
- Pfizer$28K
- plus $76K from 19 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 134 | $116,206 |
| Abbott | 140 | $100,027 |
| Amgen | 21 | $51,026 |
| AstraZeneca | 74 | $36,705 |
| Novartis | 30 | $34,702 |
| Pfizer | 27 | $28,474 |
| Bridgebio Pharma, Inc. | 15 | $24,680 |
| Bayer | 24 | $16,362 |
| Boehringer Ingelheim | 27 | $16,204 |
| Cvrx, Inc. | 24 | $6,736 |
| Lilly USA, LLC | 5 | $3,451 |
| Medtronic(2 entities) | 17 | $2,177 |
| Abiomed | 31 | $2,017 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 24 | $1,319 |
| United Therapeutics Corporation | 15 | $923 |
| E.r. Squibb & Sons, L.L.C. | 9 | $773 |
| Merck | 6 | $434 |
| Alnylam Pharmaceuticals Inc. | 4 | $264 |
| Novo Nordisk | 3 | $253 |
| Atricure, Inc. | 4 | $203 |
| Boston Scientific | 2 | $180 |
| Amarin Pharma, Inc. | 1 | $122 |
| Vifor Pharma, Inc. | 1 | $84 |
| Scpharmaceuticals Inc. | 2 | $56 |
| Bardy Diagnostics, Inc. | 1 | $15 |
How this compares
$443,391 in reported general payments places this provider in the 80th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other advanced heart failure and transplant cardiology in Sacramento
- Gurpreet SodhiSacramento$303K
- John ChinSacramento$205K
- Zi Jian XuSacramento$144K
- Nancy LuoSacramento$118K
- Imo EbongSacramento$65K
- Ronald WittelesStanford$4.1M
- James Heywoodla Jolla$2.1M
- Eldrin LewisStanford$1.8M
- Richard WrightSanta Monica$1.7M
- Eric AdlerSan Diego$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.